Status and phase
Conditions
Treatments
About
Daprodustat (GSK1278863), is a small molecule currently in development for the treatment of anemia of chronic kidney disease (CKD). Results of the earlier studies shows that liver is involved in the clearance of Daprodustat and hence, hepatic impairment can affect Daprodustat levels in the body. This single dose study will assess the effect of liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD) of daprodustat. The study will be conducted in two parts, Part 1 will include subjects with moderate hepatic impairment and matched healthy control subjects whereas Part 2 will include subjects will either mild or severe hepatic impairment and matched healthy control subjects. Approximately 8 subjects will be included in each of the group and all subjects will receive 6 milligram (mg) of daprodustat as a single oral dose in the fasted state. Total duration of participation in the study for a subject will be up to 7 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For all subjects:
Additional inclusion criteria for Hepatically-Impaired subjects:
Additional inclusion criteria for healthy control subjects:
Exclusion criteria
For all subjects:
Exclusion criteria for Hepatically-Impaired subjects:
Exclusion criteria for healthy control subjects:
Primary purpose
Allocation
Interventional model
Masking
37 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal